Authors

Angeline Shen

MBBS, FRACP, Consultant Endocrinologist, Department of Diabetes and Endocrinology, The Royal Melbourne Hospital, Melbourne, Vic; Consultant General Physician, Department of General Medicine, The Royal Melbourne Hospital, Melbourne, Vic

Impact of semaglutide and dulaglutide shortages on Pharmaceutical Benefits Scheme prescriptions supplied for type 2 diabetes treatment

This retrospective population-based study examines semaglutide and dulaglutide prescriptions for type 2 diabetes supplied via the Pharmaceutical Benefits Scheme from January 2021 to September 2022.